Incidence of spontaneous notifications of adverse reactions with aceclofenac, meloxicam, and rofecoxib during the first year after marketing in the United Kingdom

References

• AltmanDGMachinDBryantTNStatistics with Confidence2000BristolBMJ Bks
   Google Scholar
• BombardierCLaineLReicinAComparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study GroupN Engl J Med20003431520811087881
   PubMed Web of Science ®Google Scholar
• CaulinCFrom the chemical product to the authorization of drug marketingRev Prat2002524869011949499
   PubMedGoogle Scholar
• HrachavecJBMoraMReporting of 6-month vs 12-month data in a clinical trial of celecoxib. Author replyJAMA20012862399400
   Web of Science ®Google Scholar
• LaporteJRIbanezLVidalXUpper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agentsDrug Saf2004274112015144234
   PubMed Web of Science ®Google Scholar
• LaytonDHeeleyEHuguesKComparison of the incidence rates of selected gastrointestinal events reported for patients prescribed rofecoxib and meloxicam in general practice in England using prescription-event monitoring dataRheumatology2003426223112709537
   PubMed Web of Science ®Google Scholar
• MacDonaldTMMorantSVGoldsteinJLChannelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugsGut20035212657012912856
   PubMed Web of Science ®Google Scholar
• MalhotraSPandhiPShafiqNCOX-2 inhibitors: a CLASS act or Just VIGORously promotedMedGenMed20046615208519
   PubMedGoogle Scholar
• Merck & Co.Merck anuncia la retirada voluntaria de la venta de VIOXX® en todo el mundo [online]2004 Accessed on 3 October 2004. URL: http://www.vioxx.com/vioxx/documents/spanish/vioxx_press_release.pdf
   Google Scholar
• MorideYDucruetTBoivinJFPrescription channeling of COX-2 inhibitors and traditional nonselective nonsteroidal anti-inflammatory drugs: a population-based case-control studyArthritis Res Ther20057R3334215743481
   PubMed Web of Science ®Google Scholar
• MukherjeeDNissenSETopolEJRisk of cardiovascular events associated with selective COX-2 inhibitorsJAMA2001286954911509060
   PubMed Web of Science ®Google Scholar
• OfmanJJBadamgarayEHenningJMUtilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysisAm J Med20041168354215178499
   PubMed Web of Science ®Google Scholar
• OkieSRaising the safety bar – the FDA’s coxib meetingN Eng J Med200535213
   Web of Science ®Google Scholar
• PedrosCCereczaGLaporteJRPrimeras notificaciones espontáneas de sospechas de reacciones adversas a los nuevos anti-inflamatorios selectivos sobre la ciclooxigenasa-2Med Clin200211841517
   PubMedGoogle Scholar
• PelosoPMStrategies and practice for use of nonsteroidal antiinflammatory drugsScand J Rheumatol1996105Suppl2943
   Google Scholar
• RawsonNSNourjahPGrosserSCFactors associated with celecoxib and rofecoxib utilizationAnn Pharmacother20053959760215755796
   PubMed Web of Science ®Google Scholar
• SahaiHKhurshidAStatistics in epidemiology. methods, techniques and applications1996Boca RatonCRC Pr
   Google Scholar
• SeibertKMasferrerJZhangYMediation of inflammation by cyclooxygenase-2Agents Actions199546Suppl4150
   PubMedGoogle Scholar
• SilversteinFEFaichGGoldsteinJLGastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety StudyJAMA200028412475510979111
   PubMed Web of Science ®Google Scholar
• SimonLSActions and toxicity of nonsteroidal anti-inflammatory drugsCurr Opin Rheumatol19957159667612406
   PubMedGoogle Scholar
• SinghGRosen RameyDRNSAID reduced gastrointestinal complications: the ARAMIS perspective – 1997. Arthritis, Rheumatism and Aging Medical Information SystemJ Rheumatol199851Suppl816
   Google Scholar
• TramerMRMooreRAReynoldsDJQuantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID usePain2000851698210692616
   PubMed Web of Science ®Google Scholar
• [UK MCA] Medicines and Healthcare products Regulatory AgencyMonitoring the safety and quality of medicines: Pharmacovigilance [online]2004 Accessed on 11 August 2004. URL: http://www.mhra.gov.uk
   Google Scholar
• VaneJRBottingRMMechanism of action of nonsteroidal antiinflammatory drugsAm J Med19981042S8S9572314
   PubMed Web of Science ®Google Scholar
• VaneJRInhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugsNature19712312325
   Web of Science ®Google Scholar
• [WHO] Norwegian Institute of Public HealthWorld Health Organisation Collaborating Centre for Drug Statistics Methodology [online]2004 Accessed on 3 October 2004. URL: http://www.whocc.no/atcddd
   Google Scholar
• WolfeFAndersonJBurkeTAGastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapyJ Rheumatol2002294677311908558
   PubMed Web of Science ®Google Scholar
• WolfeFFlowersNBurkeTAIncrease in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritisJ Rheumatol20022910152212022317
   PubMed Web of Science ®Google Scholar
• WolfeMMLichtensteinDRSinghGGastrointestinal toxicity of nonsteroidal anti-inflammatory drugsN Engl J Med199934018889910369853
   PubMed Web of Science ®Google Scholar
• WrightJMPerryTLBassettKLReporting of 6-month vs 12-month data in a clinical trial of celecoxibJAMA2001286239840011712925
   PubMed Web of Science ®Google Scholar
• ZhaoSZBurkeTAWheltonAComparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practiceAm J Manag Care2002815 SupplS39240012416789
   PubMed Web of Science ®Google Scholar